<DOC>
	<DOCNO>NCT00514163</DOCNO>
	<brief_summary>The primary objective study compare tumor response rate test arm ( gemcitabine+S-1 ) control arm ( gemcitabine alone ) patient unresectable pancreatic cancer</brief_summary>
	<brief_title>GEM vs GEM+TS-1 Advanced Pancreatic Cancer</brief_title>
	<detailed_description>Pancreatic cancer fifth lead cause cancer death United States . It difficult diagnose early stage 10-20 % patient candidate resection 5-year survival rate le 10 % . Patients unresectable pancreatic cancer poor prognosis . Gemcitabine , cytidine analogue , standard chemotherapeutic agent disease median survival time ( MST ) range 6 8 month . Phase Ⅲ study show combination drug , oxaliplatine CDDP , contribute survival time . TS-1 , new oral fluoropyrimidine consist 5-FU prodrug tegafur ( ftorafur , FT ) two enzyme inhibitor , CDHP ( 5-chloro-2,4-dihydroxypyridine ) OXO ( potassium oxonate ) , molar ratio 1 ( FT ) :0.4 ( CDHP ) :1 ( OXO ) , commercially available since late 90'in Japan . Phase II trial demonstrate S-1 effective single agent treatment gastric ( RR 44.6 % ) , colorectal ( RR 37.4 % ) , head neck , breast , non-small cell lung , pancreatic cancer ( 20 % ) . A combination gemcitabine TS-1 find effective promising phase Ⅱ trial metastatic pancreatic carcinoma select subject , combination therapy high rate side effect . This phase Ⅱ randomize control study compare efficacy feasibility GEM+S-1 GEM alone patient locally advance metastatic pancreatic cancer performance status 0-2 , aim patient rather ordinary clinical setting .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>1 . Histologically cytologically proven unresectable pancreatic carcinoma 2 . There must measurable lesion multislice CT 3 . ECOG Performance status 02 4 . No active cancer 5 . No previous therapy radiotherapy , chemotherapy immunotherapy 6 . Adequate organ function preserve WBC 4000/mm3 , Hb 8.0g/dl , neutrophil 2000/mm3 , platlet 100,000/mm3 , AST le 2.5 x normal le 5.0 x normal patient know liver metastasis , bilirubin le 2.0mg/dl , Ccr 60ml/min 7 . No serious complication 8 . Be able eat food 9 . Life expectancy 8 week duration 10 . Informed consent obtain 1 . Interstitial pneumonia 2 . Uncontrollable diabetes , liver dysfunction , angina pectoris , myocardial infarction onset within 3 month 3 . Serious infection 4 . Pregnant lactating female 5 . History serious drug allergy 6 . Serious complication 7 . Uncontrolled mental disorder</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>pancreatic carcinoma</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>S-1</keyword>
	<keyword>phaseⅡstudy</keyword>
</DOC>